ITV, mid-ventilation, gating or couch tracking - A comparison of respiratory motion-management techniques based on 4D dose calculations by Ehrbar, Stefanie et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
ITV, mid-ventilation, gating or couch tracking - A comparison of respiratory
motion-management techniques based on 4D dose calculations
Ehrbar, Stefanie; Jöhl, Alexander; Tartas, Adrianna; Stark, Luisa Sabrina; Riesterer, Oliver; Klöck,
Stephan; Guckenberger, Matthias; Tanadini-Lang, Stephanie
Abstract: PURPOSE: Respiratory motion-management techniques (MMT) aim to ensure tumor dose cov-
erage while sparing lung tissue. Dynamic treatment-couch tracking of the moving tumor is a promising
new MMT and was compared to the internal-target-volume (ITV) concept, the mid-ventilation (MidV)
principle and the gating approach in a planning study based on 4D dose calculations. METHODS:
For twenty patients with lung lesions, planning target volumes (PTV) were adapted to the MMT and
stereotactic body radiotherapy treatments were prepared with the 65%-isodose enclosing the PTV. For
tracking, three concepts for target volume definition were considered: Including the gross tumor volume
of one phase (single-phase tracking), including deformations between phases (multi-phase tracking) and
additionally including tracking latencies of a couch tracking system (reliable couch tracking). The ac-
cumulated tumor and lung doses were estimated with 4D dose calculations based on 4D-CT datasets
and deformable image registration. RESULTS: Single-phase tracking showed the lowest ipsilateral lung
Dmean (median: 3.3Gy), followed by multi-phase tracking, gating, reliable couch tracking, MidV and
ITV concepts (3.6, 3.8, 4.1, 4.3 and 4.8Gy). The 4D dose calculations showed the MidV and single-phase
tracking overestimated the target mean dose (-2.3% and -1.3%), while it was slightly underestimated by
the other MMT (<+1%). CONCLUSION: The ITV concept ensures tumor coverage, but exposes the
lung tissue to a higher dose. The MidV, gating and tracking concepts were shown to reduce the lung dose.
Neglecting non-translational changes of the tumor in the target volume definition for tracking results in
a slightly reduced target coverage. The slightly inferior dose coverage for MidV should be considered
when applying this technique clinically.
DOI: https://doi.org/10.1016/j.radonc.2017.05.016
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-142064
Journal Article
Accepted Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Ehrbar, Stefanie; Jöhl, Alexander; Tartas, Adrianna; Stark, Luisa Sabrina; Riesterer, Oliver; Klöck,
Stephan; Guckenberger, Matthias; Tanadini-Lang, Stephanie (2017). ITV, mid-ventilation, gating or
couch tracking - A comparison of respiratory motion-management techniques based on 4D dose calcula-
tions. Radiotherapy and Oncology, 124(1):80-88.
DOI: https://doi.org/10.1016/j.radonc.2017.05.016
2
1 
 
Received Date: 11 November 2016 
Revised Date: 19 April 2017 
Accepted Date: 20 May 2017 
 
Title page 
 
Proposed journal: Radiotherapy and Oncology 
 
 
Title: ITV, mid-ventilation, gating or couch tracking – A comparison of 
respiratory motion-management techniques based on 4D dose calculations 
 
Authors: Stefanie Ehrbar+1,2, Alexander Jöhl1,3, Adrianna Tartas1,4, Luisa Sabrina Stark1,2, Oliver Riesterer1,2, 
Stephan Klöck1,2, Matthias Guckenberger1,2, Stephanie Tanadini-Lang1,2 
 
Addresses: 
1 Department of Radiation Oncology, University Hospital Zurich (USZ), Switzerland 
2 University of Zurich, Switzerland 
3 Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, 
Switzerland 
4 University of Warsaw, Faculty of Physics, Poland 
 
+ Corresponding author:   Department of Radiation Oncology 
    University Hospital Zurich 
    Rämistrasse 100 
    CH-8091 Zurich 
+41 (0)44 255 1808  
stefanie.ehrbar@usz.ch 
     
     
 
Key words: Lung cancer, Tracking, Gating, Respiratory motion management, Stereotactic body radiation therapy, 
4D dose calculation 
 
 
 
 
 
 
 
 
 
 
 
 
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as  
doi: 10.1016/j.radonc.2017.05.016 
This article is protected by copyright. All rights reserved. 
  
2 
 
Abstract 
Purpose: Respiratory motion-management techniques (MMT) aim to ensure tumor dose coverage 
while sparing lung tissue. Dynamic treatment-couch tracking of the moving tumor is a promising new 
MMT and was compared to the internal-target-volume (ITV) concept, the mid-ventilation (MidV) 
principle and the gating approach in a planning study based on 4D dose calculations. 
Methods: For twenty patients with lung lesions, planning target volumes (PTV) were adapted to the 
MMT and stereotactic body radiotherapy treatments were prepared with the 65%-isodose enclosing 
the PTV. For tracking, three concepts for target volume definition were considered: Including the gross 
tumor volume of one phase (single-phase tracking), including deformations between phases multi-
phase tracking) and additionally including tracking latencies of a couch tracking system (reliable couch 
tracking). The accumulated tumor and lung doses were estimated with 4D dose calculations based on 
4D-CT datasets and deformable image registration. 
Results: Single-phase tracking showed the lowest ipsilateral lung Dmean (median: 3.3 Gy), followed by 
multi-phase tracking, gating, reliable couch tracking, MidV and ITV concept (3.6, 3.8, 4.1, 4.3 and 4.8 
Gy). The 4D dose calculations showed the MidV and single-phase tracking overestimated the target 
Dmean (-2.3% and -1.3%), while it was slightly underestimated by the other MMT (<+1%).  
Conclusion: The ITV concept ensures tumor coverage, but exposes the lung tissue to a higher dose. 
The MidV, gating and tracking concept were shown to reduce the lung dose. Neglecting non-
translational changes of the tumor in the target volume definition for tracking results in a slightly 
reduced target coverage. The slightly inferior dose coverage for MidV should be considered when 
applying this technique clinically. 
  
3 
 
Introduction 
Respiratory tumor motion increases the position uncertainty in radiotherapy. Lung tumors were 
reported to move up to 34 mm in cranial-caudal direction [1]. To achieve local tumor control, 
respiratory motion has to be addressed in the treatment planning and delivery. This is commonly done 
by increasing the treatment volume to cover the whole extent of motion. Advanced motion-
management techniques (MMT) aim to further mitigate the tumor motion, eventually resulting in a 
reduction of treatment volume, associated with reduced healthy tissue irradiation.  
In stereotactic body radiotherapy (SBRT), the total radiation dose is delivered to the patient in only a 
few high-dose fractions with steep dose gradients outside the treatment volume. In contrast to 
conventional therapy, lung SBRT shows reduced toxicities and better quality of life [2]. Despite already 
low toxicities, some patient groups could further benefit from a reduction in treatment volume. Oligo-
metastatic patients often get multiple courses of radiation therapy, and therefore the cumulative 
organ dose has to be kept as low as possible. Also for patients with large sized or centrally located lung 
tumors, the organ dose could be reduced with MMT in order to make SBRT with curative intent at all 
feasible. 
The prominent motion-management techniques under free breathing are the internal-target-volume 
(ITV) concept, the mid-ventilation (MidV) principle, respiratory gating, and dynamic target tracking. 
The ITV concept [3] considers the tumor motion with a motion-encompassing safety margin. The MidV 
concept [4] considers the motion as random positioning error in a probabilistic safety margin 
calculation, leading to smaller treatment volumes than the ITV concept. Both concepts are passive 
motion-management techniques, which require only the a priori extent of tumor motion. Gating and 
tracking are active techniques, which require information on the tumor position in real-time. The 
gating concept [5, 6] restricts the irradiation to a predefined tumor position window, reducing the 
treatment volume, but increasing the overall treatment time. The tracking concept allows for volume 
reduction with continuous irradiation using real-time compensation of the tumor motion. Tracking can 
be realized by either following the motion with the treatment beam [7, 8, 9], or by counter-steering 
the patients, using the robotic couch, in real-time according to their internal tumor motion [10, 11, 12, 
13].  
For a comparison of these techniques, an estimation of the healthy tissue doses, as well as an 
estimation of the target doses are required. The accumulated dose to a moving tumor will differ from 
the dose estimation from a three-dimensional treatment plan due to interplay, gradient and density 
effects. The gradient effect is the blurring of the dose when the tumor moves through an 
inhomogeneous dose field. The temporal interplay between dynamic treatment delivery and tumor 
motion changes the occupation time of different tumor regions in the high dose region and causes the 
regions to receive higher or lower doses than expected. Density effects are caused by the respiration-
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induced density variations, yielding different dose distributions in different respiratory phases. 
Additionally, the density of a respiratory phase differs from the density of the average CT 
reconstruction, which is often used for dose calculation. Therefore, this would yield a different dose 
to the tumor.  
All of these effects can be considered in four-dimensional (4D) dose calculations to better estimate the 
dose to a moving tumor by a recalculation of time-resolved treatment plans on a 4D-CT image set 
combined with deformable dose summation. This has already been done in previous studies for ITV, 
MidV and tracking concepts [14, 15, 16, 17, 18, 19]. The established differences were considered to be 
negligibly small. However, treatment planning was performed with a homogeneous prescription to the 
PTV. SBRT is often prescribed inhomogeneously to the 60-80% isodose-line. This leads to higher dose 
gradients within the target which may lead to higher sensitivity of the accumulated dose to motion 
effects, which has not yet been investigated. 
Planning [20, 21, 7, 17, 18] and phantom studies [22, 23] on comparison of MMT have been performed. 
But so far, no study has compared all four techniques in a consistent study design while considering 
tumor coverage and lung dose sparing as endpoints.  
This planning study was designed to evaluate the benefits and drawbacks of ITV, MidV, gating and 
couch tracking concepts for lung SBRT. 4D dose calculations were performed to investigate not only 
reductions in lung doses but also target dose coverage and thus to evaluate the robustness of the 
treatment concepts against respiratory motion.  
 
Material and Methods 
Patients 
Twenty patients with thoracic lesions were selected based on their tumor motion, having a minimal 
motion of 5 mm and at least half of the patients were requested to have motion larger than 10 mm. 
All 4D-CT scans were taken on a SOMATOM Definition AS Open (Siemens AG, Germany) CT scanner 
prior to treatment. Ten respiratory phases were reconstructed based on the respiratory signal of the 
Real-time Position Management System (Varian Medical System, Palo Alto, CA, USA). The respiratory 
phases were phase-binned (13 patients) or amplitude-binned (7-patients). The tumor motion was 
calculated as the maximal displacement of the center of volume (COV) of the tumor in all respiratory 
phases. Patient characteristics as diagnosis, respiratory period, GTV size and tumor motion amplitude 
are listed in the Supplement.   
 
Contouring 
The GTV was delineated by a radiation oncologist in a 4D-CT phase between inhale and exhale (initial 
contouring phase). The GTV contour was then propagated to the other phases with deformable image 
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registrations performed with the MIM Software (MIM Software Inc., Cleveland OH, USA). No 
extensions from GTV to clinical target volume were added. The GTVs of the ten phases were used for 
the definition of the radiotherapy target volumes (TV) for six treatment concepts. The TV were 
contoured in the following ways:  
 
- ITV concept: The union of all GTVs was taken as internal target volume (ITV). 
- MidV: The time-weighted average of the tumor positions was calculated and the GTV closest 
to it was defined as mid-ventilation TV [4, 24, 25]. 
- Gating: The union of the GTVs within a 30%-duty cycle around end of inhale were combined 
to a gating TV. 
- Single-phase Tracking: The TV was restricted to only the GTV in the MidV-phase. This single-
phase approach neglects any target deformation and rotation or residual compensation errors 
at the planning stage. 
- Multi-phase Tracking: To additionally consider non-translational changes of the target volume, 
all ten GTVs were overlaid according to their COV and the union was taken as TV. 
- Reliable Couch Tracking: Residual tracking errors (see below) of a couch tracking system and 
non-translational changes were considered in this approach. The ten GTVs were also overlaid 
according to their COV, but to include the residual tracking errors, the COV shifted apart 
according to the residual motion amplitude and then combined to the TV.  
 
Based on these target volumes, the planning target volumes (PTV) were derived by adding a margin 
according to the van-Herk formula [4] (see Supplement). The margins for the MidV concept ranged 
from 5 to 15 mm depending on the motion and direction. A fixed 5 mm margin was used for the ITV, 
gating and tracking approaches mainly addressing delineation uncertainties [26]. 
 
Treatment planning 
SBRT treatments with two volumetric modulated arcs were planned and optimized in Eclipse (Varian 
Medical System, Palo Alto, CA, USA), version 11.0.31, and doses were calculated with the analytical 
anisotropic algorithm with a beam energy of 6 MV in flattening filter free mode. A dose of 40.5 Gy in 
3 fractions was prescribed to the 65%-isodose line around the PTV. At least 95% of the PTV had to 
receive the prescribed dose (D95PTV>40.5 Gy). The dose was optimized to increase towards the tumor 
center, covering 95% of the TV with at least the 87%-isodose line (D95TV>54.6 Gy). This second 
constraint was used to guide the high-dose to the central part of the PTV and to cover the volume of 
high interest with a higher dose than the PTV. The lung, heart and spinal cord doses were kept as low 
as possible, while for the spinal cord a strict constraint of not more than 18 Gy was used. For each 
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patient, a distinct treatment plan was generated for each of the six treatment concepts and dose 
distributions were calculated. This dose distribution is in the following referred to as the 3D dose. 
 
Residual tracking error 
Tracking latencies or mechanical restrictions of the tracking hardware can lead to an offset between 
the expected and actual target position. This offset, or tracking error, has to be considered during 
treatment planning and included into the TV either as additional margin, or as COV shift as described 
above. The tracking errors were evaluated for the prototype couch tracking system described by Lang 
et al. [10]. The measurement set-up, which was also described by Jöhl et al. [27], and evaluation of the 
residual motion amplitude and compensation rates are described in the Supplement. In summary, the 
motion of a robot was measured with laser triangulation (optoNCDT 1302-100, Micro Epsilon 
Messtechnik GmbH & Co. KG, Ortenburg, Germany) and compensated by a Protura treatment couch 
(CIVCO Medical Solutions, Coralville, IA, USA). The couch motion was also measured with a laser and 
compared to the robot’s motion curve to evaluate the residual tracking error of each patient. 
 
4D dose calculation 
The 3D dose only gives an estimation of the dose, which will be received by the tumor. But the 
accumulated dose in the moving tumor will differ from this estimation due to the gradient, interplay 
and density effects. 4D dose calculations, considering these respiratory effects, were performed as 
earlier described in Ehrbar et al. [28]. The process is schematically drawn in Figure 1. The treatment 
beam was split into arc segments to create ten sub-plans, which were temporally assigned to and 
recalculated on the ten phase-CTs. For the amplitude-binned 4DCTs, a time-weighting of the phases 
was additionally introduced. For tracking, the dynamic compensation behavior of the treatment couch 
was considered by shifting the beam isocenter according to the tumor COV of each phase. For the 
reliable-couch-tracking concept, an offset between beam isocenter and tumor COV according to the 
residual motion was introduced at this calculation step. In the last step, the time-resolved dose was 
summed up according to deformable registrations between the phase CTs. This was performed with 
the 4D dose accumulation tool of the MIM Software (version 6.6.1). For the ITV, MidV and tracking 
concepts, the dose was accumulated on the initial contouring phase, and for gating on the mid-gating 
phase. A comparison of mid-gating and initial contouring phase as accumulation phases for gating is 
shown in the Supplement. 
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Dose evaluations 
Target and lung dose parameters were reported. For the target, the mean dose (Dmean), the dose to 
95% of the target volume (D95), the near maximum dose (D1: dose to 1% of the target) and the 
homogeneity index (HI) were evaluated. For HI the following definition was used: 
𝐻𝐻𝐻𝐻 (%) = 𝐷𝐷1 − 𝐷𝐷99
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
∗ 100 
These dose parameters were evaluated on the individual TV for the 3D dose, and directly on the GTV 
of the accumulation phase for the 4D dose. The TV used in the treatment planning were chosen for 
the comparison, since they are assumed to give a closer approximation of the GTV dose coverage than 
the PTV in presence of inhomogeneous SBRT dose distributions. Comparisons between 3D and 4D 
target dose parameters were performed with paired Wilcoxon sign-rank tests. Spearman correlations 
of the dose differences with tumor motion and with tumor size were investigated. 
The 4D dose distributions were also used to report on lung dose. The mean dose (Dmean) and the 
relative volumes receiving more than 5 Gy and 20 Gy (V5 and V20) were evaluated for the ipsilateral 
lung, excluding the GTV volume. The lung parameters were normalized per patient to the values of the 
ITV concept. Reduction in lung dose of the different MMT were investigated. Comparisons were 
performed with a paired Wilcoxon sign-rank test. Spearman correlations of the relative lung doses with 
tumor motion and with tumor size were investigated. For all comparisons and correlations, a two-sided 
significance level of 5% was used (p-value < 0.05). 
 
Results   
Residual tracking error 
The 20 patients showed a median motion amplitude of 3.3 mm (25- and 75-percentiles: 1.8, 6.5) and 
11.6 mm (8.5, 13.2) in AP and SI direction, respectively. With couch tracking, the residual motion 
amplitudes were reduced to 0.8 mm (0.51, 2.21) and 2.6 mm (1.42, 3.99) in AP and SI. Detailed results 
are shown in the Supplement. The patient-individual residual motion amplitude was used to spread 
out the GTV volumes in the reliable couch tracking approach. 
 
Tumor coverage 
The planning constraints (D95PTV>40.5 Gy, D95TV>54.6 Gy, OAR constraints) were achieved for all MMT, 
with only minor differences in 3D dose calculations regarding tumor coverage of the TVs. The 4D dose 
calculations showed, that all concepts were able to cover the GTV with the prescribed PTV dose 
(D95GTV>40.5 Gy). However, there were differences found when comparing the 3D dose of the TV with 
the 4D dose of the GTV. Figure 2 shows the 3D and 4D dose parameters. The 4D dose calculations of 
target Dmean and D95 gave slightly higher values than the corresponding 3D calculated parameters 
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for the ITV concept, gating and reliable couch tracking, while lower values were found for MidV and 
single-phase tracking. No significant differences in target Dmean and D95 were found for multi-phase 
tracking. For all MMT, except single-phase and multi-phase tracking, increases in near maximum dose 
(D1) were found, while HI was increased for all except gating. Overall, the 4D target dose was closest 
to the 3D dose for gating and multi-phase tracking. Median dose differences and percentiles are listed 
in Table 1 together with the correlation coefficients of the significant correlations.  
For gating, the 4D dose accumulation was performed with accumulation against the mid-gating phase 
and also against the initial contouring phase. Here only the accumulation against mid-gating are 
shown, while a comparison of both accumulation phases for gating are shown in the Supplement. 
 
PTV reduction and OAR sparing 
When compared to the ITV concept, the single-phase tracking showed the largest reduction in PTV size 
(median: -40%), followed by gating, multi-phase tracking, MidV and reliable couch tracking (-25%, -
25%, -23% and -16%). Analogously, a reduction in Dmean, V5 and V20 of the lung was achieved. The 
medians and percentiles of the absolute PTV sizes and lung doses are listed in Table 2. Figure 3 shows 
the PTV size and ipsilateral lung values normalized to the values of the ITV concept. The medians and 
percentiles of the normalized reductions are listed in Table 3 together with correlation coefficients of 
the significant correlations. Positive correlations to tumor size indicate a larger relative benefit for 
patients with smaller tumors. Negative correlations to tumor motion indicate a larger relative benefit 
for larger motion amplitudes. The lung benefits for MidV were mostly correlated to the tumor size, 
while the tracking approaches were found to be correlated primarily to tumor motion. 
 
Discussion 
The management of intrafractional lung tumor motion is important to reach dose coverage of moving 
tumors and to minimize dose related lung toxicities. ITV, MidV, gating and three couch tracking 
approaches were compared in a planning study including 4D dose calculations to evaluate their ability 
of lung dose sparing and tumor dose coverage. All techniques enabled a reduction in lung dose, when 
compared to the conservative ITV concept. Largest benefit in ipsilateral lung Dmean was shown for 
single-phase tracking (-29%) followed by multi-phase tracking and gating with similar reductions (-18% 
and -19%) and by MidV and reliable couch tracking (-15% and -12%). However, the single-phase 
tracking and MidV approach showed a decrease in tumor coverage (ΔD95: -3.2% and -6.3%, ΔDmean: 
-1.3% and -2.3%). It is worth mentioning that all techniques were able to fulfill the primary goal to 
deposit more than the prescribed PTV edge dose of 40.5 Gy within the GTV. With the multi-phase 
tracking and reliable couch tracking approaches, it was possible to consider deformations and tracking 
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latencies, resulting in adequate tumor coverage (ΔD95: -0.1% and +0.6%, ΔDmean: +0.1% and +0.6%), 
but with a lower reduction in lung dose. 
The reduction in lung dose is directly related to the reduction in PTV size enabled by the MMT. Depuydt 
et al. [7] reported a PTV reduction of 35% (range: 16%-53%) when changing from the ITV concept to a 
tracking scenario. A similar reduction of 37% (10%-50%) was found here for the single-phase tracking 
scenarios. Guckenberger et al. [17] quantified the decrease in lung Dmean and V20, changing from ITV 
over to a MidV or gating approach. They showed a lower benefit for the MidV concept and a higher 
benefit for the gating concept compared to our work. This is mainly caused by a different adaptation 
of the MidV concept with dose prescription to the accumulated GTV and by the smaller gating duty 
cycle of only 12.5% employed by them, compared to our 30%.  
The 4D dose calculation showed a slight increase in target Dmean and D95 for the ITV, gating and 
reliable couch tracking approaches when compared to the 3D dose. This can be explained by the use 
of a planning TV which is larger than the GTV. Treatment plans for SBRT also show a dose increase 
within the TV with the lowest TV doses at the edges of the volume. The moving GTV itself is not always 
occupying the lower dose regions and therefore accumulates a higher dose than estimated by the TV.  
A more prominent decrease in target Dmean and D95 was shown for MidV and single-phase tracking. 
For the MidV concept, this can be explained by the nature of the concept itself, where 90% of the 
patients were expected to receive 95% of the prescription dose. The decrease for the single-phase 
tracking approach is of a different nature. The TV was restricted to the GTV of one phase. Deformations 
and rotations of the tumor throughout the respiratory phases were neglected at the planning stage. 
These changes of the tumor volume over the respiratory cycle were considered in the multi-phase 
tracking approach, which was able to fully account for these effects. 
The changes seen in target D1 can be attributed mainly to gradient and interplay effects. The single-
phase and multi-phase tracking show only a spread out in D1, but no significant increase, whereas for 
the other concepts, the D1 was increased.  
Guckenberger et al. [29] showed that the biologically effective dose (BED) to the CTV, estimated with 
the 4D calculation, did better fit the tumor control probability curve than the 3D doses at the PTV 
margin. Further studies showed that the PTV maximal dose is a better prognostic factor for tumor 
control than the PTV enclosing dose [30, 31] and that dose prescription to the GTV median dose rather 
than the PTV enclosing provides a more robust method for treating lung lesions with SBRT [32]. An 
evaluation of the 4D dose to the CTV, in our case GTV, is therefore recommendable for the comparison 
of dynamic treatment delivery techniques. The fractionation scheme and prescription dose of the 
present study resulted in a biological effective dose (BED) of 192 Gy BED to the PTV maximal dose. Also 
the estimated 4D maximal dose to the GTV ranged from 182 to 200 Gy BED over all techniques and 
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patients. In this dose region, the techniques are expected to result in similar tumor control 
probabilities. This conclusion might change with a lower dose prescription.      
End-of-inhale was chosen as gating window and the dose for the gating plan was accumulated to the 
middle-most phase of the gating window (mid-gating). The decrease in lung dose for the gating 
approach is therefore not only caused by the decrease in PTV size, but also by the increase in lung 
volume at end-of-inhale. For all the other MMT, the initial contouring phase was used for dose 
accumulation to minimize registration errors in the dose accumulation process and to evaluate on the 
same contours. However, the gating plans would only be applied to the patient with the tumor in the 
gating window. Therefore, the accumulation to the mid-gating phase represents best the accumulated 
tumor dose. However, choosing the mid-gating phase as accumulation phase might give an advantage 
in the tumor coverage for gating, since all phases are close to the accumulation phase and therefore 
might be less influenced by registration errors. 
Another way to evaluate accumulated tumor dose are direct dose measurements in a motion 
phantom. This was performed in one of our former studies [33] with an anthropomorphic, deformable 
thorax phantom. For gating and tracking, superior dose coverage and better lung sparing was shown 
than for ITV and MidV concepts. For tracking, a single-phase planning approach was used, since the 
tumor was a rigid sphere, and resulted in similar dose coverage to the gating approach. 
Limitations of a couch tracking system were considered in the reliable couch tracking approach by 
including the residual motion amplitude in the TV delineation. The latency and mechanical limitations 
cause the couch to lag behind the tumor position. The residual motion is thus largest at the steep 
motion gradients. The Protura couch was not initially designed for dynamic motion compensation and 
its maximal speed is restricted to 16 mm/s. Patients with tumor motion faster than this will be 
insufficiently compensated. Couch tracking systems with higher compensation speed, as for example 
the PerfectPitch couch (Varian), would better compensate the tumor motion and therefore reduce the 
residual motion.  
Including the residual tracking errors into the TV definition resulted in increased target volumes, and 
therefore less sparing of the lung. In the presented reliable couch tracking approach, the treatment 
volume was increased to cover the full extent of residual motion. However, the tumor motion is only 
offset during a small amount of the overall treatment time. This indicates that the used approach is 
overprotective and it is cumbersome to conduct a patient-individual evaluation and TV adaption. 
Alternatively, a combined tracking-MidV approach could be considered, including the residual motion 
and tumor deformation into the PTV margin as statistical uncertainties. Patient individual estimations 
of the residual motion can be made based on the respiration during CT acquisition in combination with 
a performance model of the treatment couch [27].   
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A laser system was used as motion feedback for the couch tracking. It is only capable of measuring 
surface motions. To detect internal motion, fluoroscopy imaging of gold markers or detection of 
implanted electromagnetic beacons can be used [34, 35, 36]. These systems, however, have a longer 
latency time than the employed laser system. An increased latency would also increase the residual 
motion. This effect can be mitigated by applying prediction filters [37] or regularly updated external-
internal motion correlations [38].  
The 4DCT images do not fully reduce image artifacts, caused by the tumor motion [39, 40, 41]. These 
artifacts affect the tumor delineation, TV definition and 4D dose calculation. It is therefore 
questionable to what extent the differences seen in the GTVs of the ten phases are caused by image 
artifacts or by real deformations of the tumor, and which tracking concept (single- or multi-phase) is 
more appropriate. 
For the comparison of different dynamic treatment techniques, the respiration dynamics have to be 
considered to evaluate the ability of each technique to cover the tumor with dose or to spare healthy 
tissue. The effects of the respiratory behavior of the tumor were therefore considered in 4D dose 
calculations. Further uncertainties as set-up and delineation errors or changes in respiratory cycle were 
neglected in the calculations, however, they were expected to affect the techniques equally. 
The 4D dose calculations were based on several assumptions. First, a regular respiratory period  (3.4 s 
for phase-based and 5.1-9.18 s for amplitude-based reconstructed 4DCTs) was assumed to facilitate 
the temporal assignment of the arc segments to the phases. Second, fractionation effects were 
neglected in the calculation, which could mitigate the impact of the interplay effect and third, the 
assignment of the arc segments was done with regarding only one starting phase per patient. Rao et 
al. [42] showed that the 4D-to-3D dose differences for lung SBRT using an ITV concept are only to a 
minor extent caused by the interplay effect and also the choice of the respiratory starting phase for 
the assignment of the arc segments did not change the difference substantially. This would mean that 
the 4D calculations were assumed to be insensitive against the length of the respiratory period and 
the assignment starting phase. We did evaluate the dependence on the respiratory starting phase for 
one patient (see supplement). For the gating and tracking treatments, no relevant dependence was 
found (spread < 0.4 Gy), but for ITV and MidV concept, the Dmean and D1 showed a spread of 0.8 Gy 
and 1.7 Gy, respectively, for different starting phases. By including 20 patients to the study but only 
one starting phase, we considered to sufficiently cover the interplay variation by the patient sample 
size. To better judge the impact of the interplay effect for different motion-management techniques,  
elaborate investigations beyond the scope of this study should be performed. 
Also the accuracy of the deformable image registration directly influences the accuracy of the 4D dose 
calculation. Kadoya et al. [43] showed for the MIM software a mean 3D registration error of 3.29 mm 
between end-of-inhale to end-of-exhale CT phases and that the likelihood of registration error 
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increased with initial displacement. In the present work, the registrations of the 4DCT phases were 
performed against a respiratory phase in the middle of the breathing cycle. This reduced the maximal 
displacement to be registered by the deformable image registration algorithm and thereby minimized 
the registration error. On the other hand, the middle phase is more prone to image artifacts caused by 
tumor motion which restrict the accuracy of the 4D dose calculations. 
This study is valid for dynamic treatment-couch tracking at a conventional linear accelerator, but might 
also be valid for other tracking types to some extent. As planning strategy,  a single- or multi-phase 
tracking approach is often used, but the delivery technique might differ between tracking types and 
change the results.  
 
Conclusion 
The use of the ITV concept for lung SBRT ensures excellent tumor coverage, but exposes the healthy 
lung tissue to an unnecessarily high amount of radiation. The treatment volume and lung doses can 
easily be reduced by employing other motion-management techniques as MidV, gating or couch 
tracking concepts. However, 4D dose calculations should be employed to evaluate the tumor dose 
coverage for these techniques. Tumor deformation and system latencies should be considered in the 
treatment planning approaches for tumor tracking to fully ensure target coverage. 
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Table 1: GTV coverage: Median values of the differences between 4D and 3D dose calculations (4D  – 
3D value) are listed together with 25%- and 75%-percentiles. Correlation coefficients of the differences 
with tumor motion amplitude or tumor size are given for the significant correlations (p<0.05). 
 
ΔDmean (%)  ΔD95 (%) 
 
Median (prctiles) R motion R size  Median (prctiles) R motion R size 
ITV Concept 0.8 (0.4, 1.2) - -  1.1 (0.2, 1.4) - - 
MidV Concept -2.3 (-3.0, -1.7) - -  -6.3 (-8.5. -4.9) - - 
Gating 0.4 (0.4, 0.9) - -  0.7 (0.4, 1.1) - - 
Single-phase 
Tracking -1.3 (-2.0, -0.9) - 0.52  -3.2 (-5.1, -2.4) -0.49 - 
Multi-phase 
Tracking 0.1 (-0.3, 0.4) - 0.67  -0.1 (-0.6, 0.6) - 0.58 
Reliable Couch 
Tracking 0.6 (0.0, 0.8) - 0.54  0.6 (0.0, 1.2) - 0.59 
 
ΔD1 (%)  ΔHI (pp) 
 
Median (prctiles) R motion R size  Median (prctiles) R motion R size 
ITV Concept 2.4 (1.1, 3.2) - -0.47  2.5 (0.2, 3.7) - - 
MidV Concept 0.9 (0.0, 1.6) - -  10.2 (7.4, 12.1) - - 
Gating 0.2 (0.1, 0.6) - -  0.1 (-0.5, 0.6) - - 
Single-phase 
Tracking -0.3 (-0.7, 0.4) - 0.78  5.3 (3.0, 7.8) 0.56 - 
Multi-phase 
Tracking 0.0 (-0.2, 0.4) - 0.58  1.0 (0.0, 3.1) 0.61  
Reliable Couch 
Tracking 0.6 (0.0, 1.3) - 0.55  0.5 (0.2, 1.6) 0.49 - 
prctiles: (25-percentile, 75-percentile), R: Spearman rank correlation coefficient, Δ: 4D minus 3D value 
 
 
Table 2: Absolute PTV size and ipsilateral lung dose parameters: Median values of PTV size, lung 
Dmean, V5 and V20 are listed together with the 25%- and 75%-percentiles.  
 PTV size (cc)  Dmean (Gy)  V5 (%)  V20 (%) 
 Median (prctiles)  Median (prctiles)  Median (prctiles)  Median (prctiles) 
ITV Concept 32 (23, 72)  4.8 (3.2, 6.6)  27.8 (19.7, 35.8)  6.4 (3.2, 8.0) 
MidV Concept 24 (17, 59)  4.3 (2.6, 5.7)  24.2 (15.7, 32.3)  4.8 (2.5, 6.5) 
Gating 23 (17, 56)  3.8 (2.7, 5.0)  22.2 (15.5, 26.9)  4.3 (2.3, 5.8) 
Single-phase 
Tracking 19 (14, 44)  3.3 (2.4, 4.7)  20.1 (13.9, 26.4)  3.7 (2.0, 4.8) 
Multi-phase 
Tracking 23 (16, 51)  3.6 (2.8, 5.1)  21.4 (14.8, 28.2)  4.5 (2.4, 5.9) 
Reliable Couch 
Tracking 26 (19, 60)  4.1 (2.9, 5.6)  23.2 (15.8, 32.4)  5.3 (2.7, 6.8) 
prctiles: (25-percentile, 75-percentile) 
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Table 3: Normalized PTV size and ipsilateral lung dose parameters: Median reduction of the 
parameters (PTV size, lung Dmean, V5 and V20), normalized by the values of the ITV concept plan, are 
listed together with the 25%- and 75%-percentiles. Correlation coefficients are given for the significant 
correlations (p<0.05) of the reduction with tumor motion or tumor size.  
 
Δ relative PTV size (%)  Δ relative Dmean (%) 
 
Median (prctiles) R motion R size  Median (prctiles) R motion R size 
MidV Concept -23 (-29, -18) - 0.45  -15 (-20, -11) - - 
Gating -25 (-30, -18) -0.57 -  -19 (-27, -16) -0.48 - 
Single-phase 
Tracking -40 (-42, -33) -0.69 -  -29 (-32, -23) -0.68 - 
Multi-phase 
Tracking -25 (-33, -21) -0.81 -  -18 (-24, -14) -0.79  
Reliable Couch 
Tracking -16 (-22, -11) -0.55 -  -12 (-17, -8) -0.47 0.47 
 
Δ relative V5 (%)  Δ relative V20 (%) 
 
Median (prctiles) R motion R size  Median (prctiles) R motion R size 
MidV Concept -11 (-18, -7) - 0.58  -22 (-30, -17) - - 
Gating -18 (-25, -12) - 0.51  -26 (-34, -20) - - 
Single-phase 
Tracking -28 (-33, -18) -0.47 0.58  -38 (-41, -34) -0.47 - 
Multi-phase 
Tracking -19 (-26, -10) -0.57 -  -26 (-30, -18) -0.67 - 
Reliable Couch 
Tracking -14 (-21, -7) -0.45 -0.53  -17 (-20, -8) -0.47 - 
prctiles: (25-percentile, 75-percentile), R: Spearman rank correlation coefficient, Δ: Normalized difference to ITV concept 
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Figure 1: 4D dose calculation: (Top left) The initial treatment plan with its 3D dose distribution on the 
planning CT (here the average CT). (1) Separation of the treatment plan into arc segments assigned to 
the respiratory phases (different gray levels). (2) Recalculation of time-resolved sub-plans on the phase 
CTs, resulting in a time-resolved dose. (3) Dose summation on a mid-respiration phase according to 
deformation fields resulting in a 4D dose distribution. 
16 
 
 
Figure 2: Results of the 3D and 4D dose calculations: The Dmean, D95, D1 and HI of the TV from the 
original treatment plans (3D: gray boxplots) and the accumulated GTV doses (4D: white boxplots). 
Planning constraints for D95 are highlighted in light gray. Arrows indicate significant differences 
between 3D and 4D dose. Triangles and circles indicate significant correlations of these differences 
with tumor motion amplitude or tumor size, respectively. 
17 
 
 
 
Figure 3: Normalized PTV size and 4D dose parameters of the ipsilateral lung: The parameters were 
normalized with the values of the ITV concept plan for each patient. Triangles and circles indicate 
significant correlations of the normalized parameters with tumor motion amplitude (all positively 
correlated) or tumor size (all negatively correlated), respectively. 
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1 Patient characteristics
Out of the twenty patients, eight were treated for primary disease (four non-small and four small
cell lung cancer) and twelve had metastatic lesions. Most selected lesions were located in the lower
lung lobe, since patients with pronounced tumor motion were preferred in the selection. Respiratory
periods ranged from 1.8 to 5.8 s, gross tumor volumes (GTV) from 0.6 to 79.3 cc and 3D tumor motion
amplitudes from 4.9 to 27.8 mm (see Table 1 for details).
2 Margin calculation
The planning target volumes (PTV) were derived by adding a margin to the target volume (TV). The
margin was calculated using systematic (Σ) and random (σ) positioning errors of the tumor according
to an adapted version of the van-Herk formula [1]:
M = 2.5 ∗
√
Σ2Setup + Σ
2
BL + Σ
2
Del + Σ
2
PD + β ∗
√
σ2Setup + σ
2
BL + σ
2
TM + σ
2
P − β ∗ σP
For a margin to ensure coverage of the target volume with 95% of the dose in 90% of the cases, a β-
value of 1.64 was used. A σP of 6.4 mm was used (according to [2]) to account for the beam penumbra
in lung tissue. Setup errors (ΣSetup, σSetup) were assumed to be compensated using CB-CT imaging
and therefore set to zero. For baseline shifts over the course of treatment, values from Lang et al. [3]
were used (ΣBL=0.99 mm, σBL=1.08 mm). For delineation uncertainties, a value of ΣDel=1.70 mm
was used. Only for the MidV margin, the tumor motion was taken into the calculation as random
1
Supplementary Table 1: Patient Characteristics: Tumor type and localization, respiratory period from
RPM curves, GTV size and tumor motion amplitude from 4D-CT.
Tumor motion (mm)
Patient Type Localization Period (s) GTV size (cc) LR AP SI 3D
1 NSCLC l LL 2.7 79.3 1.7 1.8 4.2 4.9
2 NSCLC l LL 3.8 6.0 1.9 7.4 17.7 19.2
3 Metastasis r LL 4.8 3.0 3.0 2.7 6.3 7.5
4 Metastasis l LL 3.0 0.6 0.8 1.8 5.1 5.5
5 Metastasis l LL 3.0 37.7 4.3 2.9 21.8 22.4
6 NSCLC l LL 3.3 17.3 1.0 5.3 11.8 13.0
7 SCLC r UL 4.8 4.4 3.9 3.6 7.2 9.0
8 Metastasis l LL 4.2 7.2 0.8 4.6 11.0 11.9
9 Metastasis r ML 4.6 7.8 2.7 1.9 9.1 9.7
10 Metastasis l LL 4.8 3.7 2.8 3.0 14.1 14.7
11 NSCLC r LL 5.8 16.4 6.2 8.9 25.6 27.8
12 Metastasis l LL 4.0 3.9 3.5 7.0 17.4 19.0
13 Metastasis l LL 4.5 2.3 1.6 0.7 12.8 13.0
14 Metastasis l LL 4.2 15.5 4.2 7.3 11.9 14.5
15 SCLC l LL 3.8 25.2 1.8 7.2 11.5 13.6
16 SCLC r ML 3.9 20.8 0.9 1.2 11.9 12.0
17 Metastasis r UL 5.7 2.2 1.1 4.4 12.1 12.9
18 SCLC r LL 3.1 3.8 1.9 6.4 9.8 11.9
19 Metastasis l LL 1.7 9.1 1.6 1.2 6.6 6.9
20 Metastasis l LL 3.2 1.8 1.1 1.1 9.0 9.1
Median 3.9 6.6 1.9 3.3 11.6 12.5
25-prctile 3.1 3.5 1.1 1.8 8.5 9.1
75-prctile 4.6 16.6 3.1 6.5 13.2 14.6
(N)SCLC: (Non) Small Cell Lung Cancer, l: left, r: right, LL/ML/UL: Lower/Middle/Upper Lobe,
prctile: percentile
positioning error (σTM ). The standard deviation of the motion (= random error) was approximated
to be 1/3 of the motion amplitude in each direction. Additionally, a fraction of 1/10 of the motion was
used as systematic error (ΣPD) to account for the binned data representation of the 4D-CT phases
which could cause an error in the phase determination (PD) of the MidV phase. The MidV margins
ranged from 5 to 15 mm depending on the motion. A 5-mm margin for no motion was used for the
ITV, gating and tracking approaches.
3 Residual tracking error
3.1 Methods
For the estimation of the residual motion during tracking, internal tumor motion curves of the patients
are required. This internal tumor motion was simulated by scaling the external RPM signal during 4D-
CT acquisition with the internal tumor motion amplitude retrieved from the 4D-CT. The signal was
cut to 100 seconds and scaled, such that the 5%-to-95%-percentile range of the motion signal equaled
the internal tumor motion amplitude from the 4D-CT. This patient specific motion was then simulated
with the robotic hexapod H-840.5PD (Physik Instrumente GmbH & Co. KG, Karlsruhe/Palmbach,
2
Germany). The motion of the hexapod was measured via laser triangulation using the displacement
sensor optoNCDT 1302-100 (Micro Epsilon Messtechnik GmbH & Co. KG, Ortenburg, Germany),
which was attached to the treatment couch. This laser system has a latency of 1 ms, a measuring
rate of 500 Hz and a resolution of 50 µm. The laser signal was used as input signal for the tracking
system. A Simulink interface (The MathWorks, Inc., Natick, MA, USA) managed the conversion of
the input signal to couch control signals. No prediction filter was applied to the signal. The Protura
treatment couch (CIVCO Medical Solutions, Coralville, IA, USA) was employed to compensate the
motion. The speed of the robotic couch system was limited to 16 mm/s. The couch and laser system
combined had a total system latency of 57 ms [4]. The couch was set to compensate the motion in
superior-inferior (SI) and anterior-posterior (AP) direction. The couch motion was monitored with a
second laser system attached to the immobile floor. The measurement setup is shown in Figure 1.
Supplementary Figure 1: Measurement setup: The robotic Hexapod simulates the patient’s tumor
motion, which is monitored by Laser I, attached to the table. The detected motion is converted to
couch control signals to compensate this motion in either AP or SI direction. The motion of the
treatment couch is monitored by Laser II, attached to the floor. The motion signals from Laser I and
II can be compared to calculate the residual tumor motion.
The two laser signals were compared against each other. In an ideal tracking scenario, the sum
of both signals would always equal zero. In a non-ideal tracking scenario, the sum corresponds to
the residual offset between plan isocenter and beam isocenter. The 5%-to-95%-percentile difference of
the residual motion signal was calculated and defined as the residual motion range, which was used
for the definition of the tiTV. The tracking performance was additionally evaluated by calculating an
amplitude compensation rate (ACR) using the ratio of the residual motion amplitude (Ares) and the
initial tumor motion amplitude (A):
ACR(%) = (1 − Ares
A
) ∗ 100
A value of 100% means full compensation of the tumor motion by the treatment couch, a value
of 0% means no compensation at all. The root-mean-square error (RMSE) of the tumor motion
signal and the residual motion signal were calculated. The tracking performance was also evaluated
by calculating an error compensation rate (ECR) using the ration of the residual RMSE (RMSEres)
and the initial RMSE (RMSEinit):
ECR(%) = (1 − RMSEres
RMSEinit
) ∗ 100
The ECR is less influenced by short-duration spikes, which occur at the steep motion gradients,
than the ACR and therefore gives a more holistic performance evaluation. To fully ensure tumor
coverage in the tracking-ITV approach, the ACR was used for contouring.
3.2 Results
The laser signals of three measurements for the determination of the residual motion amplitude are
shown in Figure 2. These represent the measurements with the worst, the median and the best
3
Supplementary Figure 2: Residual motion in SI: The tumor motion (black), simulated with the Hexa-
pod, and the negative couch counter-motion (dark gray) were measured simultaneously with two
triangulation laser sensors. The difference of these signal is the residual tumor motion (thick bright
gray). The results with the worst, median and best tracking performance are shown (patient 5, 11
and 17).
amplitude compensation rate. The residual motion is largest in between inhale and exhale, where the
steepest motion gradients occur. The evaluated residual motion amplitudes, RMSE and compensation
rates are shown in Table S2. Over all patients, median ACR in AP and SI direction of 71% and 77%,
and ECR of 89% and 95%, respectively, were found.
4 Dependence on accumulation phase for gating
In the dose accumulation process of the 4D dose calculation, an accumulation phase has to be chosen.
The deformation fields between the phases and this accumulation phase are used to warp the dose. In
the manuscript, the mid-gating phase in the middle of the gating window was chosen as accumulation
phase, while for the other methods, the initial countouring phase inbetween inhale and exhale was
used. Choosing the accumulation phase in the middle of all relevant phases minimizes the registration
error, which increases with increased distance of the lesions inbetween the phases. For gating, all
relevant phases (i.e. phases with applied dose) are close to the accumulation phase. This gives an
advantage to gating, since the other methods have also some relevant phases further away from the
accumulation phase. The alternative would be to use the same accumulation phase for gating as for
the other methods. However, this poses a disadvantage to the accumulated gating phase, since all
relevent phases are at end of inhale and threrfore maximally influenced by the registration error. Both
strategies for dose accumulation are compared in Figure 3, with 4D dose accumulation against the
initial contouring phase (4DMid) and against the mid-gating phase at end of inhale (4DEOI). The
tumor coverage (D95) was slightly inferior for the 4DMid dose compared to the 3D and 4DEOI dose.
Especially, there were two outliers with drastically lower Dmean and D95 in the 4DMid accumulation.
No significant difference in the maximal dose (D1) was found.
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Supplementary Table 2: Tracking performance: Residual motion amplitude, root mean square error
(RMSE), amplitude and error compensation rates (ACR and ECR) for SI and AP motion compen-
sation.
Res. Amplitude ACR Initial RMSE Res. RMSE ECR
(mm) (%) (mm) (mm) (%)
Patient AP SI AP SI AP SI AP SI AP SI
1 0.50 0.96 72 77 0.44 2.38 0.04 0.12 90 95
2 3.78 7.93 49 55 6.56 38.39 1.76 7.98 74 79
3 0.48 0.98 82 85 0.93 5.19 0.04 0.17 96 97
4 0.53 1.18 70 77 0.42 3.63 0.05 0.28 88 93
5 3.32 17.55 −16 19 1.10 63.50 1.30 34.00 7 42
6 2.19 4.19 58 64 4.47 22.61 0.79 2.73 83 88
7 0.78 1.20 78 83 1.72 6.98 0.08 0.25 95 96
8 1.15 1.95 75 82 2.61 15.14 0.16 0.53 94 96
9 0.37 1.32 81 86 0.54 12.22 0.03 0.35 94 97
10 0.65 1.95 79 86 2.27 49.12 0.10 0.91 95 98
11 2.42 6.14 73 76 11.45 94.46 0.78 4.35 93 95
12 2.54 5.49 64 68 6.47 39.54 0.83 3.35 86 91
13 0.19 2.48 73 81 0.06 19.93 0.02 0.83 72 96
14 2.15 3.13 70 74 9.88 26.37 0.71 1.44 93 94
15 2.00 2.62 72 77 7.45 18.88 0.48 0.84 93 96
16 0.53 3.37 57 72 0.20 18.24 0.04 1.14 79 94
17 0.89 1.72 80 86 2.69 20.96 0.11 0.47 96 98
18 2.21 2.97 65 70 5.92 14.16 0.63 1.20 89 92
19 0.79 2.54 35 61 0.43 14.12 0.19 1.98 67 87
20 0.49 2.81 54 69 0.16 11.79 0.04 0.97 76 92
Median 0.84 2.58 71 77 2.00 18.56 0.14 0.94 89 95
25-prctile 0.52 1.62 58 69 0.44 12.12 0.04 0.44 78 91
75-prctile 2.19 3.58 76 83 6.06 29.38 0.73 2.16 94 96
Res.: residual, ACR/ECR: amplitude/error compensation ratio, RSME: root mean square error
prctile: percentile
5 Dependence on starting phase for 4D dose calculation
In the 4D dose calculation process, the arc segments were assigend to the different respiratory phases
to account for interplay effects. The assignment starts at one specific phase. The result of the 4D
calculation with interplay might therefore depend on the choice of this starting phase. The dependence
on this starting phase was investigated for patient 6 with a tumor motion amplitude of 13 mm. The
4D dose to the tumor was calculated for each technique with five different starting phases, except for
gating, where only the three phases in the gating window were considered as starting phases. Also a
4D calculation neglecting the interplay effect was performed for each concept by simply assigning the
whole plan to each phase but only with a proportion of the monitor units. The results are shown in
Figure 4. For the gating and tracking treatments, no relevant dependence on the starting phase was
found (spread <0.4 Gy). In these cases, the 4D dose could simply be estimated without regarding
interplay effects. But for ITV and MidV concept, the mean and maximal dose (Dmean and D1)
showed a spread of about 0.8 Gy and 1.7 Gy, respectively, depending on the starting phase. However,
the minimal dose (D99), which gives the coverage of the target volume, was barely affected by the
interplay effect itself.
5
Supplementary Figure 3: Target dose for gating. The Dmean, D95, D1 and HI of the TV from
the original treatment plans (3D: gray boxplots) and the accumulated GTV doses (4D: white box-
plots). 4DMid: accumulation against initial countouring phase inbetween inhale and exhale. 4DEOI:
accumulation against mid-gating phase at end of inhale. Arrows indicate significant differences.
6
Supplementary Figure 4: Dependence of 4D dose calculation on the starting phase for the arc-segment
assignment. The 3D dose parameters (circles) of the target volume and the 4D dose parameters of
the GTV with (crosses) and without (triangles) consideration of interplay are shown for all motion-
mitigation techniques. Dmean: mean dose, D95/1/99: dose to 95/1/99% of volume, HI: homogeneity
index.
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